Lipum Q1: Further clinical validation - Redeye

Redeye provides a research update following the Q1 report published by Lipum earlier today. While the company reported a quarterly OPEX above our estimates, the quarter was primarily characterized by the positive phase I study results with SOL-116. The finalized Clinical Study Report further validated earlier topline results, reinforcing our positive outlook on the candidate’s clinical potential.

Länk till analysen i sin helhet: https://www.redeye.se/research/1097032/lipum-q1-further-clinical-validation?utm_source=finwire&utm_medium=RSS